Luis Phillipe Nagem Lopes, Augusto César Sousa Raimundo, Alexander Itria, Rosângela Caetano, Luciane Cruz Lopes
{"title":"利培酮用于自闭症谱系障碍的预算影响的重新计算：使用测量需求数据的案例研究，巴西，2017-2019。","authors":"Luis Phillipe Nagem Lopes, Augusto César Sousa Raimundo, Alexander Itria, Rosângela Caetano, Luciane Cruz Lopes","doi":"10.1590/S2237-96222025v34e20240732.en","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the budgetary impact of use of risperidone for autism spectrum disorder (ASD) in the Brazilian National Health System (SUS).</p><p><strong>Methods: </strong>This is a case study with a document-based approach, which compared the estimates of the budgetary impact analyses presented in the recommendation reports of the National Commission for the Incorporation of Technologies (CONITEC) for the use of risperidone for ASD with amounts recalculated from measured demand data. The recalculation for children (0-17 years) and adults (≥18 years) was made using data from the Open Health Intelligence Room platform on the dispensing of risperidone in the SUS, considering a three-year time period (2017-2019).</p><p><strong>Results: </strong>The total budgetary impact over three years of use of risperidone for ASD showed differences between measured demand (children: BRL 10,389,702.70; adults: BRL 15,075,767.80) and that estimated by CONITEC in its recommendation reports (children: R$ 6,579,809.00; adults: R$ 9,877,790.18).</p><p><strong>Conclusion: </strong>The budgetary impact of use of risperidone for ASD, based on measured demand, differed from the impact initially predicted in CONITEC's recommendation reports.</p>","PeriodicalId":520611,"journal":{"name":"Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil","volume":"34 ","pages":"e20240732"},"PeriodicalIF":2.0000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342727/pdf/","citationCount":"0","resultStr":"{\"title\":\"Recalculation of the budgetary impact of risperidone use for Autism Spectrum Disorder: a case study using measured demand data, Brazil, 2017-2019.\",\"authors\":\"Luis Phillipe Nagem Lopes, Augusto César Sousa Raimundo, Alexander Itria, Rosângela Caetano, Luciane Cruz Lopes\",\"doi\":\"10.1590/S2237-96222025v34e20240732.en\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To analyze the budgetary impact of use of risperidone for autism spectrum disorder (ASD) in the Brazilian National Health System (SUS).</p><p><strong>Methods: </strong>This is a case study with a document-based approach, which compared the estimates of the budgetary impact analyses presented in the recommendation reports of the National Commission for the Incorporation of Technologies (CONITEC) for the use of risperidone for ASD with amounts recalculated from measured demand data. The recalculation for children (0-17 years) and adults (≥18 years) was made using data from the Open Health Intelligence Room platform on the dispensing of risperidone in the SUS, considering a three-year time period (2017-2019).</p><p><strong>Results: </strong>The total budgetary impact over three years of use of risperidone for ASD showed differences between measured demand (children: BRL 10,389,702.70; adults: BRL 15,075,767.80) and that estimated by CONITEC in its recommendation reports (children: R$ 6,579,809.00; adults: R$ 9,877,790.18).</p><p><strong>Conclusion: </strong>The budgetary impact of use of risperidone for ASD, based on measured demand, differed from the impact initially predicted in CONITEC's recommendation reports.</p>\",\"PeriodicalId\":520611,\"journal\":{\"name\":\"Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil\",\"volume\":\"34 \",\"pages\":\"e20240732\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342727/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1590/S2237-96222025v34e20240732.en\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S2237-96222025v34e20240732.en","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Recalculation of the budgetary impact of risperidone use for Autism Spectrum Disorder: a case study using measured demand data, Brazil, 2017-2019.
Objective: To analyze the budgetary impact of use of risperidone for autism spectrum disorder (ASD) in the Brazilian National Health System (SUS).
Methods: This is a case study with a document-based approach, which compared the estimates of the budgetary impact analyses presented in the recommendation reports of the National Commission for the Incorporation of Technologies (CONITEC) for the use of risperidone for ASD with amounts recalculated from measured demand data. The recalculation for children (0-17 years) and adults (≥18 years) was made using data from the Open Health Intelligence Room platform on the dispensing of risperidone in the SUS, considering a three-year time period (2017-2019).
Results: The total budgetary impact over three years of use of risperidone for ASD showed differences between measured demand (children: BRL 10,389,702.70; adults: BRL 15,075,767.80) and that estimated by CONITEC in its recommendation reports (children: R$ 6,579,809.00; adults: R$ 9,877,790.18).
Conclusion: The budgetary impact of use of risperidone for ASD, based on measured demand, differed from the impact initially predicted in CONITEC's recommendation reports.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
